Safety Data and Beneficial Effects of the Combined Oral Contraceptive Ethinylestradiol 0.03 mg/Chlormadinone Acetate 2 mg (Belara®)A 13-Cycle Observational Study in Routine Clinical Practice

被引：0

作者：

Daphnee S. Pushparajah

Petra Röhm

Kornelia Höschen

Dagmar Albers

Christina Nowack

机构：

[1] Grünenthal GmbH,Department of Science

[2] Grünenthal GmbH,Department of Statistics

[3] Grünenthal GmbH,Department of Clinical Operations

[4] Grünenthal GmbH,undefined

来源：

Clinical Drug Investigation | 2011年 / 31卷

关键词：

Acne; Combine Oral Contraceptive; Premenstrual Syndrome; Breast Tenderness; Breakthrough Bleeding;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Background: The monophasic hormonal combined oral contraceptive (COC) ethinylestradiol (EE) 0.03 mg/chlormadinone acetate (CMA) 2 mg (Belara®) has been shown to have good long-term efficacy and tolerability.

引用

页码：121 / 134

页数：13

共 19 条

[1] Safety Data and Beneficial Effects of the Combined Oral Contraceptive Ethinylestradiol 0.03 mg/Chlormadinone Acetate 2 mg (Belara®) A 13-Cycle, Observational Study in Routine Clinical Practice
Pushparajah, Daphnee S.
Roehm, Petra
Hoeschen, Kornelia
Albers, Dagmar
Nowack, Christina
CLINICAL DRUG INVESTIGATION, 2011, 31 (02) : 121 - 134
[2] Evaluation of efficacy, safety and effects on symptoms of androgenization of a generic oral contraceptive containing chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg
Hadji, Peyman
Biskup, Jutta
Boekhoff, Jelena
Ziller, May
Bonn, Michael
Rovati, Lucio
CONTRACEPTION, 2012, 86 (04) : 359 - 365
[3] Contraceptive Efficacy and Tolerability of Chlormadinone Acetate 2mg/ Ethinylestradiol 0.03mg (Belara®)Results of a Post-Marketing Surveillance Study
G. Schramm
D. Steffens
Clinical Drug Investigation, 2002, 22 : 221 - 231
[4] Contraceptive efficacy and tolerability of chlormadinone acetate 2mg/ethinylestradiol 0.03mg (Belara®) -: Results of a post-marketing surveillance study
Schramm, G
Steffens, D
CLINICAL DRUG INVESTIGATION, 2002, 22 (04) : 221 - 231
[5] Contraceptive efficacy and safety of a low-dose oral contraceptive, (0.03 mg ethinyl oestradiol and 2 mg chlormadinone acetate) Belara®, over three medication cycles
Spona, J.
Binder, N.
Hoeschen, K.
Feichtinger, W.
EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2008, 13 (01): : 39 - 48
[6] Extended Cycles with the Combined Oral Contraceptive Chlormadinone Acetate 2 mg/Ethinylestradiol 0.03 mg Pooled Analysis of Data from Three Large-Scale, Non-Interventional, Observational Studies
Goeretzlehner, Gunther
Waldmann-Rex, Susanne
Schramm, Georg A. K.
CLINICAL DRUG INVESTIGATION, 2011, 31 (04) : 269 - 277
[7] In vivo and in vitro endothelial effects of the oral contraceptive containing 2mg Chlormadinone acetate/0.3 mg Ethinylestradiol
Franceschini, S.
Vieira, C. S.
Andozia, M. B.
Tolloi, M. R. T.
Sa, M. F. S.
Ferriani, R. A.
HUMAN REPRODUCTION, 2011, 26 : I247 - I248
[8] Extended Cycles with the Combined Oral Contraceptive Chlormadinone Acetate 2 mg/Ethinylestradiol 0.03 mgPooled Analysis of Data from Three Large-Scale, Non-Interventional, Observational Studies
Gunther Göretzlehner
Susanne Waldmann-Rex
Georg A.K. Schramm
Clinical Drug Investigation, 2011, 31 : 269 - 277
[9] Six-Month Evaluation of the Benefits of the Low-Dose Combined Oral Contraceptive Chlormadinone Acetate 2 mg/Ethinylestradiol 0.03 mg in Young WomenResults of the Prospective, Observational, Non-Interventional, Multicentre TeeNIS Study
Sabine Anthuber
Georg A.K. Schramm
Marie-Luise S. Heskamp
Clinical Drug Investigation, 2010, 30 : 211 - 220
[10] Six-Month Evaluation of the Benefits of the Low-Dose Combined Oral Contraceptive Chlormadinone Acetate 2 mg/Ethinylestradiol 0.03 mg in Young Women Results of the Prospective, Observational, Non-Interventional, Multicentre TeeNIS Study
Anthuber, Sabine
Schramm, Georg A. K.
Heskamp, Marie-Luise S.
CLINICAL DRUG INVESTIGATION, 2010, 30 (04) : 211 - 220

← 1 2 →